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ABSTRACT
In this thesis, the role of genetic variation of human JC and BK polyomaviruses 
was investigated by characterizing JCPyV and BKPyV strains present in urine, 
viruses are established human pathogens causing clinical manifestations almost 
exclusively in immunosuppressed patients. Immunosuppression allows lytic JCPyV 
infection in the brain, which is a hallmark of severe brain disease, progressive 
treatment is currently available leaving reduction of immunosuppression as the only 
therapy option.
Mutations within the viral genome affect pathogenicity of JCPyV, and the same 
has been suggested for BKPyV. Although PML is always associated with mutated 
neurotropic JCPyV strains, the exact content of mutations, as well as where, when, 
and how neurotropic strains develop is unknown. Mutations are frequently seen in 
BKPVAN-associated BKPyV strains as well, but their association with the pathogenesis 
of BKPVAN remains elusive.
First, we performed single-molecule real-time sequencing of complete JCPyV 
genomes from three PML patients and characterized all mutations within the viral 
regulatory region and the major capsid protein of each individual virus strain. We 
PML patient. Mutations in the viral regulatory region and in the major capsid protein 
gene seem necessary for PML pathogenesis. Moreover, the presence of an archetype-
development of PML.
urine of twenty stable kidney transplant patients and one patient with extremely rare 
JCPVAN. Contrary to PML, mutations within the JCPyV genome seem not necessary 
mediated immunity, may play a role in the pathogenesis of JCPVAN.
In the third and fourth studies, we characterized BKPyV regulatory regions 
from the plasma and urine samples of kidney transplant patients with or without 
patient but also very small populations of mutated BKPyV strains were detected. 
Interestingly, viral microRNA expression, as measured in the plasma of nine 
development of BKPVAN, but even low amounts of mutated strains may affect 
pathogenicity of BKPyV by regulating the expression of viral microRNAs.
This thesis contributes to the understanding of the role of genetic variation of 
JCPyV and BKPyV in the pathogenesis of PML, JCPVAN, and BKPVAN. Viral mutations 
seem necessary for the development of PML in the brain, but not for BKPVAN and 
JCPVAN in the kidney where other factors may play a role. The results help improving 
the diagnostic methods for the prognosis and prevention of these severe diseases.
IV
TIIVISTELMÄ (ABSTRACT IN FINNISH)
Väitöskirjan tarkoituksena oli tutkia ihmisen JC- ja BK-polyoomavirusten geneettisen 
muuntelun merkitystä PML-taudissa ja polyoomavirusnefropatiassa sekvensoimalla 
ja karakterisoimalla viruskantoja potilasnäytteistä. Nämä virukset aiheuttavat 
vakavia kroonisia tauteja lähes yksinomaan immuunipuutteisilla potilailla, 
joilla immuunipuolustuksen heikkeneminen mahdollistaa elimistössä piilevien 
virusten reaktivaation ja lyyttisen virusinfektion. Progressiivinen multifokaalinen 
gliasoluissa. Lyyttinen BK-polyoomavirusinfektio munuaisissa aiheuttaa BK-
polyoomavirusnefropatiaa munuaisensiirtopotilailla. Nefropatia voi harvinaisissa 
tapauksissa olla myös JC-polyoomavirusinfektion aiheuttama. Polyoomavirus-
parantaa tautien ennustetta. 
Mutaatiot JC-polyoomaviruksen ja mahdollisesti myös BK-polyoomaviruksen 
perimässä vaikuttavat virusten taudinaiheuttamiskykyyn. PML-tautiin liittyy aina 
muuntuneen, neurotrooppisen JC-polyoomaviruskannan kehittyminen elimistössä. 
Ei tiedetä missä, milloin, tai miten neurotrooppiset kannat kehittyvät, tai millaisia 
mutaatioita vaaditaan PML-taudin kehittymiseen. Mutaatioita tapahtuu myös BK-
polyoomaviruksen perimässä, mutta niiden merkitystä BK-polyoomavirusnefropatian 
kehittymisessä ei tiedetä.
Ensimmäisessä osajulkaisussa karakterisoitiin kaikki JC-polyoomaviruskannat 
kolmen PML-potilaan selkäydinnesteestä. Työssä osoitettiin, että PML-tautiin voi liittyä 
samanaikaisesti useita, viruksen geenisäätelyalueen ja kapsidiproteiinigeenin osalta 
muuntuneita neurotrooppisia kantoja. Toisaalta arkkityyppisen kaltainen viruskanta 
yhdellä PML-potilaalla viittaisi siihen, että pienetkin viruksen geenisäätelyalueen 
muutokset olisivat riittäviä PML-taudin kehittymiselle.
Toisessa osajulkaisussa tunnistettiin muuntumattomia, arkkityyppisiä JC-
polyoomaviruskantoja kahdenkymmenen oireettoman munuaisensiirtopotilaan ja 
yhden JC-polyoomavirusnefropatiapotilaan virtsasta. Vaikuttaisi siltä, että toisin 
kuin PML-taudissa, muutokset viruksen perimässä eivät ole välttämättömiä JC-
polyoomavirusnefropatian kehittymiselle vaan muilla tekijöillä, kuten soluvälitteisellä 
immuniteetilla, on suurempi merkitys.
Kolmannessa ja neljännessä osajulkaisussa osoitettiin, että myös BK- 
polyoomavirusnefropatian kehittymiseen voisi liittyä arkkityyppinen virus. Kaikkien 
paitsi yhden tutkitun munuaisensiirtopotilaan plasmassa ja virtsassa arkkityyppiset 
viruskannat olivat vallitsevia. Useimmilla potilailla havaittiin myös pieniä määriä 
muuntuneita viruskantoja, ja samoilla potilailla viruksen mikro-RNA-tasot olivat 
korkeampia. Pienetkin muuntuneiden viruskantojen määrät voisivat siis vaikuttaa 
BK-viruksen taudinaiheuttamiskykyyn säätelemällä esimerkiksi viruksen mikro-RNA-
ekspressiota.
Väitöskirjatyö lisää tietämystä JC- ja BK-polyoomavirusten geneettisen 
muuntelun merkityksestä PML-taudin ja polyoomavirusnefropatian kehittymisessä: 
muutokset viruksen perimässä näyttäisivät olevan tärkeitä aivojen PML-taudin, 
mutta eivät munuaisten polyoomavirusnefropatian kehittymiselle. Saadut tulokset 




Alterations in the immune system function may allow opportunistic viral infections. In 
the event of prolonged immunosuppression, human polyomaviruses may reactivate 
from latency and cause severe clinical manifestations. Today, a total of four human 
infection in the brain might result in a neurodegenerative brain disease, progressive 
cell polyomavirus is currently the only cancer-associated human polyomavirus 
predisposing to the development of aggressive neuroendocrine cancer, Merkel cell 
treatment is currently available, more knowledge on the factors contributing to viral 
pathogenicity and development of polyomavirus-associated diseases is needed.
Mutations within the viral genome are a prerequisite for PML, and a role of 
viral mutations have been suggested for BKPVAN as well. Such mutations may alter 
region of the major capsid protein VP1 may change host cell tropism from kidney 
mutations needed for the development of PML or BKPVAN. 
detection and characterization of extremely small viral populations present in 
biological samples. Millions to billions of sequence reads can be produced from single 
template molecules in hundreds of thousands of parallel reactions in a single run 
genomes can be reliably characterized. MPS techniques show promise in molecular 
In this thesis, sequence variation of JCPyV and BKPyV and its contribution 





pathogenic microbes. Two overlapping, yet distinct, defense mechanisms of the 
system comprising of macrophages, dendritic cells, innate lymphoid cells, neutrophils, 
eosinophils, basophils, natural killer T cells, various signal molecules such as the 
complement system, as well as anatomical and physiological barriers such as skin, 
mucus, and low pH. The cells of innate immunity recognize pathogens by binding 
receptors. Although the innate immune system reacts rapidly to non-self molecules, 
memory against the pathogen. 
Some cells of innate immunity, such as dendritic cells, act as antigen-presenting 
cells and activate an adaptive immune system that consists of T and B lymphocytes. 
Both lymphocytes are derived from the hematopoietic stem cells of bone marrow; 
develops long-lasting immunologic memory against the pathogen. T lymphocytes 
of the infected cell. Activated CD4-positive helper T lymphocytes release cytokines 
that activate both innate and adaptive immune systems including B lymphocytes. 
B lymphocytes are responsible for the humoral immune-response and produce 
role in controlling the latency of human polyomaviruses and thereby preventing the 
development of polyomavirus-associated diseases. 
1.1.1 Viral infections in immunosuppressed patients
Multiple factors may contribute to the perturbation of the immune system 
function including acquired viral infections such as HIV, genetics, age, surgery, 
chemotherapy, and immunosuppressive therapy used to prevent allograft rejection 
after transplantation or for treatment of disease. Long-lasting immunosuppressive 
condition may however predispose to opportunistic viral infections caused by 
latent viruses persisting in the organism. For instance, the clinically most important 
viral infections after solid-organ transplantation are cytomegalovirus, and Epstein-
associated opportunistic viral infections together with hepatitis B and C viruses, and 
Common to all these viruses is the establishment of latency within the organism that 
can be disturbed by prolonged immunosuppression.
Opportunistic viral infections in immunosuppressed patients have high mortality 
and morbidity. Reactivation of Epstein-Barr virus may lead to the development of post-




major goal during immunosuppressive therapy is thus to prevent and effectively treat 
such life-threatening viral infections.
Human polyomaviruses are restricted human pathogens with potential to cause 
severe clinical manifestations. Human polyomaviruses belong to the family of 
tumors in their natural host. The research of  human polyomaviruses was facilitated 
given the oncogenic potential of SV40 in rodents, yet it still remains controversial 
whether SV40 can indeed be carcinogenic to humans. For decades, JC polyomavirus 
the genus, and it was not until the development of the state-of-the-art techniques 
discovery of new human polyomaviruses was accelerated. Today, a total of thirteen 
member was discovered in 2017 but has not yet been assigned to a polyomavirus 
latency within a host cell are characteristic to all human polyomaviruses, they are also 
known to cause several non-malignant neurological, nephrological, and cutaneous 
are almost exclusively seen after deterioration of immune system function, which is 
thought to allow the reactivation of human polyomavirus replication.
 
Seroprevalence
Human polyomaviruses are ubiquitous; the seroprevalence of most human 
most human polyomaviruses are inconclusive, however, as serological studies 
have mainly been conducted on the clinically most relevant human polyomaviruses 
Among immunocompetent adults the seroprevalence for both MCPyV and TSPyV is 
geographic differences and different immune reactions against different human 
polyomaviruses, which in turn suggests variation in the biology of these viruses. 
Contrary to other human polyomaviruses, the seroprevalence of TSPyV and JCPyV 
Serological evidence supports the idea that primary infections by most human 
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and host susceptibility of different human polyomaviruses. Infection by one human 
polyomavirus seems not to give immunity to other polyomavirus infections: adults 
Due to demographic factors and geographic distribution, the reported 
seroprevalences of some polyomaviruses, such as Saint Louis polyomavirus 
methods have drawbacks: most methods are based on VP1 with high amino acid 
identity among human polyomaviruses, and the consequent cross-reactivity makes it 
also share high amino acid similarity in their major regulatory protein, large T 
demographical, methodological, and virological factors on the seroprevalence of 
human polyomaviruses, one can expect more accurate seroprevalences as more 
serological data accumulates.
 Seroprevalence and disease associations of thirteen human polyomaviruses and 
Lyon IARC polyomavirus. 
Human polyomavirus 1 BKPyV 1971 BKPVAN, hemorrhagic cystitis
Human polyomavirus 2 JCPyV 1971 PML, granule cell neuronopathy, meningitis, JCPVAN
Human polyomavirus 3 KIPyV 2007 Respiratory disease 42-98
Human polyomavirus 4 WUPyV 2007 Respiratory disease 57-99
Human polyomavirus 5 MCPyV 2008 Merkel cell carcinoma
2010 Pruritic and dyskeratotic dermatosis
Human polyomavirus 7 HPyV7 2010 Pruritic and dyskeratotic dermatosis
Human polyomavirus 8 TSPyV 2010 Trichodysplasia spinulosa 75-91
Human polyomavirus 9 HPyV9 2011 Unknown 17-70
Human polyomavirus 10 HPyV10 2012 32-100
Human polyomavirus 11 STLPyV 2013 Unknown 57-93
Human polyomavirus 12 HPyV12 2013 Unknown 2-97
Human polyomavirus 13 NJPyV 2014 Unknown
Human polyomavirus 14 LIPyV 2017 Unknown 5-7
Abbreviations: BKPyV, BK polyomavirus; JCPyV, JC polyomavirus; KIPyV, Karolinska Institute polyomavirus; WUPyV, 
human polyomavirus 7; TSPyV, Trichodysplasia spinulosa polyomavirus; HPyV9, human polyomavirus 9; HPyV10, 
human polyomavirus 10; STLPyV, Saint Louis polyomavirus; HPyV12, human polyomavirus 12; NJPyV, New Jersey 
polyomavirus; LIPyV, Lyon IARC polyomavirus; BKPVAN; BK polyomavirus-associated nephropathy; PML, progressive 
multifocal leukoencephalopathy; JCPVAN; JC polyomavirus-associated nephropathy.
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Host cells and suggested routes of transmission
Partly due to the high host-receptor variability, the transmission routes of the different 
is assumed asymptomatic and several transmission routes have been proposed. It 
seems plausible that transmission takes place in the respiratory or the gastrointestinal 
tract, or in direct skin contact. First, BKPyV and less frequently JCPyV DNA has been 
lavage and nasopharyngeal aspirates of children; these sites can also serve as 
Fecal-oral transmission has been suggested for some human polyomaviruses. 
Replication of HPyV10 may occur in the gastrointestinal tract as it has been detected 
tract has also been suggested as a site of primary infection for HPyV12 and STLPyV 
and HPyV9, may spread via direct skin contact as they seem to be part of the 
. NJPyV has been only detected 
discovered human polyomaviruses and larger studies are needed to determine the 



























Discovery of human polyomaviruses.
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The structural knowledge of polyomavirus capsid structures comes from SV40 
studies. All polyomaviruses have a non-enveloped icosahedral capsid with the 
enclosed, circular, double-stranded DNA genome molecule. The genome is small, 
The genome of all human polyomaviruses has similar organization and it consists 
and late viral gene regions activated either before or after the onset of viral genome 
replication, respectively.
The early and late gene regions encode for regulatory or structural proteins 
in opposite strands, respectively. All human polyomaviruses express two regulatory 
replication and gene expression. Some human polyomaviruses harbor open reading 
MCPyV and TSPyV also produce truncated spliced variants of LTag, 57kT and 21kT, 
contribute to transformation.
Besides regulatory proteins, all human polyomaviruses encode for the structural 
capsid proteins VP2 and VP3 are produced from the same mRNA using different 
conserved but does contain stretches of highly variable regions responsible for the 
variation seen in the antigenic properties of human polyomaviruses. Further, variation 
in the host cell receptor recognition region of VP1 may contribute to receptor 
Bidirectional viral replication and regulation of gene expression by the NCCR is 



















Phylogeny of human polyomaviruses. Clustal Omega multiple sequence alignment 
based on the nucleic acid identity of LTag among human polyomaviruses.
 
Following primary infection, all human polyomaviruses establish a latency within an 
organism. The immune system seems to be crucial in controlling the viral latency, as 
human polyomaviruses cause severe clinical manifestations almost exclusively in 
associated with the development of an aggressive skin cancer, Merkel cell carcinoma 
Trichodysplasia spinulosa is a benign hyperproliferative skin disease 
characterized by alopecia of the eyebrows, and the presence of follicular papules 
have been diagnosed in solid organ transplant patients and in patients suffering from 
Intriguingly, trichodysplasia spinulosa may also result from a primary TSPyV infection 
thought to be required for disease onset.
MCPyV is so far the only human polyomavirus known to be causative in human 
MCPyV-positive Merkel cell carcinomas have better prognosis than MCPyV-negative 
truncation of the carboxy-terminal end of LTag, and possibly also in ALTO, seem to 
The growing body of evidence suggests that other human polyomaviruses 
and dyskeratotic dermatosis in immunosuppressed as well as in immunocompetent 
Literature review
in gastroenteritis of immunosuppressed and immunocompetent children has 
pathogens remains to be validated.
Sequence variation of recently discovered human polyomaviruses
Regardless of the stability and low mutation rate of DNA viruses, mutations frequently 
take place within human polyomavirus genome, and they may affect viral pathogenicity 
associated with trichodysplasia spinulosa is unknown. The biological impact of these 
the NCCR among human polyomaviruses seems to confer differences in cell tropism, 
Human polyomaviruses may also acquire mutations in the viral protein coding 
amino acid point mutations located both in the receptor recognition region of 
deletions occur in the VP1, LTag, and ALTO regions of pathogenic MCPyV strains 
and gastroenteritis-associated HPyV10 strains harbor VP1 and LTag point mutations 
mutations in viral pathogenicity remains to be validated.
human diseases.
KIPyV Respiratory disease NCCR, VP1, VP2, sTag, LTag Unknown
WUPyV Respiratory disease NCCR, VP1, VP2, LTag Unknown
MCPyV Merkel cell carcinoma VP1, LTag, ALTO
Dysregulation of host 
oncogenes, inhibition of viral 
replication
Pruritic and dyskeratotic 
dermatosis NCCR, VP1, LTag Unknown
HPyV7 Pruritic and dyskeratotic dermatosis
NCCR, VP1, VP2, 
VP3, LTag Unknown
TSPyV Trichodysplasia spinulosa Unknown Unknown
HPyV10 NCCR, VP1, LTag Unknown
Abbreviations: KIPyV, Karolinska Institute polyomavirus; WUPyV, Washington University polyomavirus; MCPyV, Merkel 
-
sa polyomavirus; HPyV10, human polyomavirus 10; NCCR, noncoding control region; VP1, viral protein 1; VP2, viral 




The impact of sequence variation in viral pathogenicity has been by far most 
studied in JCPyV and BKPyV. Mutations within the JCPyV genome are a prerequisite 
variation in BKPVAN. The exact characteristics and content of mutations needed for 
the pathogenicity, however, remains still elusive. It is also unknown whether individual 
contribute to the pathogenicity.
suffering from non-Hodgkin lymphoma and was later established as an etiological 
high mortality. The onset of PML is always preceded by the emergence of neurotropic 
strains having mutations within the JCPyV genome, especially rearrangements 
asymptomatic primary infection by so called archetype JCPyV with stable NCCR 
Despite of decades of intensive studies, however, the steps from primary infection to 
PML onset remain largely unsolved.
described BKPyV also in kidney transplant patients suffering from tubulo-intestinal 
major cause of graft rejection after kidney transplantation. Although BKPyV strains 
harboring mutations within the NCCR have been detected in association with BKPVAN 
Genome structure
average size is 5,000 bp. In naturally occurring viral variants the genome size may 
vary which is mainly due to variation within the NCCR: for instance, PML-associated 
the same is true for JCPyV is unknown but likely.
JCPyV and BKPyV genomes are structurally similar to other human 
origin of replication, TATA or TATA-like promoters, enhancer elements, and binding 
sites for multiple host cell transcription factors that regulate transcription of viral 
transcription factors varies from tissue to tissue and cell type to cell type, the host 
cell permissiveness for JCPyV or BKPyV replication depends on the binding sites 
9
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NCCR affect the number of transcription factor binding sites and may thus change 
viral pathogenicity.
Regulatory proteins
JCPyV and BKPyV encode for LTag and sTag that are produced from the same 
polycistronic mRNA by alternative splicing. As a major regulatory protein, LTag 
controls the replication of the viral genome and transcription of viral genes including 
domain, nuclear localization sequence, and domains for DNA binding, Zinc-binding, 
suppressor proteins pRb, p107, p130, and p53 and promotes transition to S phase of 
viral DNA thus enabling the binding of the host cell replication machinery to the origin 
late promoter via TATA-binding protein and associated factors as well as host cell 
Due to the identical amino terminal ends of T antigens, sTag of both JCPyV 
and BKPyV shares the same J domain with LTag but has a unique hypervariable 
10
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the initiation and maintenance of S phase by regulating mTOR pathway via its Zinc-
suppressors p130 and p107 highlighting the importance of cell cycle control in 
.
Structure and function of large and small T antigens. The J domain is shared by 
LTag and sTag but both proteins have unique regions: LXCXE domain, nuclear localization 
JCPyV. JCPyV produces T` -, T`135-, and T`
been shown to produce a truncated version of LTag containing J and LXCXE domains 
Unique to JCPyV and BKPyV, both viruses produce cytoplasmic agnoprotein, 
another auxiliary protein. Agnoprotein is produced at later stages of infection where it 
Both JCPyV and BKPyV agnoproteins act as viroporins by destabilizing the plasma 




pentameric capsomers each composed of 5 copies of major capsid protein VP1. 
Each capsomer is bound via amino-terminal end of VP1 to one copy of minor capsid 
VP1 harbors amino-terminal nuclear localization and genome encapsidation 
receptor recognition region that binds to glycoproteins at the host cell membrane and 
Minor capsid proteins VP2 and VP3 bind to viral genome via DNA-binding 
domain and enhance simultaneous replication and encapsidation of viral genome 
Viral microRNAs
Similar to many other viruses, JCPyV and BKPyV both encode two noncoding 
regulatory microRNA molecules: jcv-miR-J1-5p and jcv-miR-J1-3p and bkv-miR-B1-5p 
among pathogenic human polyomaviruses as microRNAs are also produced by 
and BKPyV-encoded microRNAs autoregulate viral early gene expression by binding 
to a complementary region in the 3´ end of LTag and sTag mRNA and suppressing 
by the late promoter within the NCCR, implying that mutations within the NCCR might 
inhibit the normal function of BKPyV microRNAs and subsequently enhance viral 
JCPyV- and BKPyV-encoded microRNAs have also other roles in the viral life 
cycle. The 3p microRNAs help the viruses to evade host immune response by inhibiting 
the expression of stress-induced ligand ULBP3 and preventing the activation of CTLs 
microRNAs maintain low-level viral replication that would remain unnoticed by the 
signal molecules as they are actively transported between infected and uninfected 
A role for JCPyV and BKPyV microRNAs in viral pathogenicity and development 
of polyomavirus-associated diseases has been proposed. High-level expression of 
JCPyV microRNAs, especially jcv-miR-J1-5p, has been detected in the brain of PML 
development of BKPVAN as they have been detected in urine and plasma of BKPVAN 
biomarkers for JCPyV- and BKPyV-associated diseases. 
Viral proteins and auxiliary regulatory molecules of JCPyV and BKPyV as well 
as their functions are summarized in .
12
Literature review
 Proteins and auxiliary regulatory molecules produced by JCPyV and BKPyV.
JCPyV BKPyV
Large T antigen Early
Viral replication and 
gene expression,
cell cycle control




Early - Viral replication, cell cycle control
Truncated large 




Viral replication and 
gene expression, 
virion egress
VP1 Late 354 Major capsid protein
VP2 Late 344 351 Minor capsid protein
VP3 Late 225 232 Minor capsid protein
jcv-miR-J1-5p,
bkv-miR-B1-5p Late 20-22 nt 20-22 nt
Suppression of viral early 
gene expression
jcv-miR-J1-3p,
bkv-miR-B1-3p Late 20-22 nt 20-22 nt
Suppression of viral early 
gene expression, 
immune evasion
Abbreviations: VP1, viral protein 1; VP2, viral protein 2; VP3, viral protein 3; nt, nucleotide; aa, amino acid.
Genotypes
At present, the complete protein coding region of JCPyV is used for genotyping. 
3 while genotype 5 was shown to be a subtype of genotype 3 rather than a novel 
5
Based on the differences within VP1 nucleotides 1744 to 1812, BKPyV isolates 
pathogenicity of the different BKPyV genotypes remains largely unknown although it 





genotypes I, II, and III
BKPyV
I, II, and IV
genotypes I, III, and IV
genotype I
genotypes 2, 7, and 8
genotypes 1 and 4
genotypes 3 and 6
genotypes 1, 2, and 4
Distribution of JCPyV and BKPyV genotypes. 
The narrow host cell range of JCPyV and BKPyV places restrictions on studies 
of their biology due to the lack of animal models. Primary infection is thought to 
be asymptomatic without apparent clinical symptoms. Viral life cycle starts with 
where JCPyV and BKPyV infect leukocytes in order to spread into the systemic 
host cell. Upon entry, the receptor recognition region of JCPyV VP1 attaches to the 
2A serves as 
the possible co-receptors are currently unknown.
Following attachment, the virion is internalized and subsequently transported 
into the nucleus for viral DNA replication. Different strategies are used to enter the host 
cell: JCPyV utilizes clathrin-dependent endocytosis while BKPyV enters via caveolin-
the endoplasmic reticulum the capsid is partially degraded before transportation into 
To replicate the viral genome, several cellular signaling pathways are regulated 
to the origin of replication to initiate replication and viral gene expression with the 
of infection, the cytoplasmic capsid proteins are transported to the nucleus where 
JCPyV and BKPyV are lytic viruses meaning that progeny virions are released from 
After primary infection, JCPyV and BKPyV establish latency within the organism. 
The factors contributing to the latency remain elusive but epigenetic regulation, such 
14
Literature review
incidence of PML and BKPVAN in the population indicates that many undiscovered 
factors play a role in the pathogenicity of JCPyV and BKPyV.
glycoproteins as host cell receptors. The internalization of JCPyV is mediated by clathrin-
dependent endocytosis while caveolin-dependent endocytosis is used by BKPyV. The capsid 
is partially degraded in the endoplasmic reticulum before transportation to the nucleus for 
viral DNA replication and gene expression. Reproduced with permission from Ambalathingal 
agent of PML: demyelination of the white brain matter is due to lytic infection of 
15
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treatment currently exists leaving the modulation of immunosuppression as the 
only therapy option. This can, however, lead to other complications such as PML-
worse prognosis.
For PML to occur, the replication of latent JCPyV must be reactivated and 
transmission to the brain must take place. As the vast majority of PML patients have 
some degree of underlying immunosuppression, the normal function of immune 
system seems crucial in regulating the latency and reactivation of JCPyV as well 
as transmission of neurotropic strains. Especially cell-mediated immunity, such as 
JCPyV in the brain glial cells is a hallmark of PML onset. Although mutations in the 
viral genome seem to increase the ability of neurotropic strains to replicate and infect 
Symptoms and diagnosis
Clinical features of PML are determined by the anatomical location of demyelination. 
Demyelination of the brain white matter is progressive, reaching multiple centimeters 
in diameter, and it usually affects the frontal and parietal lobes of cerebral cortex, 
features include oligodendrocytes with enlarged nuclei and giant, pleomorphic 
astrocytes with multiple nuclei; JCPyV is present in the nuclei of oligodendrocytes, 
symptoms including motoric weakness, aphasia, cognitive dysfunction, headache, 
and gait abnormalities; less than 20% of patients experience sensory loss, visual 
a life-threatening disease with poor prognosis; depending on the underlying disease 
Although magnetic resonance imaging of the brain and clinical symptoms are 
cornerstones in PML diagnosis, either presence of JCPyV DNA in the cerebrospinal 
16
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 Clinical, anatomical, and neuropathological features of PML.
• Demyelination of frontal and parietal lobes of cerebral cortex, and the subcortical cerebrum 
• Enlarged oligodendroglial nuclei and bizarre astrocytes with enlarged nuclei containing viral 
inclusion bodies
• Motoric weakness, aphasia, cognitive problems, headache, gait abnormalities, sensory loss, 
visual impairment, seizures, diplopia, and limb incoordination
• Clinical symptoms
• Magnetic resonance imaging of the brain showing demyelinated sites
viral proteins in the brain biopsy
Abbreviations: JCPyV, JC polyomavirus.
Incidence
PML onset is associated with profound and long-lasting immunosuppression 
affecting especially cellular immunity. Few case reports have questioned whether 
Today approximately 80% of PML cases are diagnosed in HIV-positive patients, 
8.4% in patients with underlying lymphoproliferative disease, approximately 5% in 
5
the incidence of PML in HIV-positive patients but the prognosis is still quite poor with 
Lymphoproliferative diseases most commonly associated with PML are 
chronic B-cell lymphocytic leukemia and Hodgkin lymphoma; PML-related mortality 
from autoimmune diseases such as systemic lupus erythematosus and rheumatoid 
patients, however, the PML risk increases with prolonged use of certain biological 
drugs. 
Literature review
 Incidence of PML.
Unknown
HIV 33.33
Transplantation solid organ 58.8
bone marrow
Lymphoproliferative disorders Unknown <10
Autoimmune disorders RA Unknown
SLE 22
Abbreviations: RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
Biological drugs and PML risk
PML risk is elevated among patients treated with certain monoclonal antibodies 
drugs are effective in treatment of autoimmune and lymphoproliferative diseases such 
as relapsing-remitting multiple sclerosis, Crohn’s disease, severe plaque psoriasis, 
non-Hodgkin lymphoma, and rheumatoid arthritis. The emergence of PML in treated 
these drugs. 
seropositivity, previous immunosuppressive treatment, and duration of natalizumab 
treatment increase PML risk: after two-year treatment of natalizumab, a ten-fold 
levels in natalizumab-treated patients without prior history of immunosuppression 
The proposed mechanism for rituximab-induced PML onset is similar to natalizumab: 
rituximab decreases the amount of circulating B lymphocytes and increases the 
Alemtuzumab has been approved for the treatment of B-cell chronic 
. Four PML 
cases have been reported among alemtuzumab-treated B-cell chronic lymphocytic 
So far only efalizumab has been completely withdrawn from the market due to 
has been accumulated on the PML risk among patients treated with newer biological 
18
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Monoclonal antibodies associated with increased PML risk.
Severe RR-MS, 
Crohn’s disease











  4 reported cases in 
22 90 100
Abbreviations: RR-MS, relapsing-remitting multiple sclerosis; RA, rheumatoid arthritis; CLL, chronic lym-
phocytic leukemia.
Immune reconstitution syndrome
Although case studies describing successful treatment of JCPyV infection in PML 
patients with chemokine receptor type 5 antagonist and 5HT2A blocker have been 
to prevent the progression and improve the prognosis of PML. Normalization of cell-
mediated immunity by withdrawal of immunosuppressive or immunomodulatory 
treatment may pose for the development of PML-IRIS. PML-IRIS is a T cell-mediated 
parenchyma resulting in a massive destruction of JCPyV-infected glial cells and 
an average mortality of 25% and 35% in natalizumab-treated multiple sclerosis and 
IRIS is achieved with treatment of corticosteroids that dampen the production of 
NCCR
Mutations are frequently observed within the genome of JCPyV, especially in the NCCR. 
NCCR and neurotropic strains having larger NCCR rearrangements. Archetype strains 
always have similar NCCR architecture that can be divided into arbitrary sequence 
. 
and enhancer elements for early and late viral gene expression. Importantly, the 
Archetype strains are thought to cause asymptomatic primary infections since they 
are occasionally found in immunocompetent and immunosuppressed individuals 
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in the archetypal NCCR but the mutations seem not alter pathogenicity of such 
Within an individual, major rearrangements, duplications, and deletions may 
take place in the NCCR of an originally archetype virus leading to the development of 
the number of binding sites for the host cell transcription factors highly expressed 
Two theories on the underlying mechanism of the development of neurotropic 
strains currently exist. First, neurotropic strains may develop in the brain supported by 
neurotropic strains could develop outside the brain for instance in the CD34-positive 
archetype JCPyV in the kidneys may allow the emergence of neurotropic strains. More 







E C EA A
Structure of archetype and neurotropic JCPyV NCCR regions. The archetypal NCCR 
NCCR of prototypic neurotropic JCPyV Mad-1 strain has duplications of A, C, and E blocks. 
Major capsid protein VP1
In addition to the mutations in the NCCR, neurotropic JCPyV strains often have 
mutations in the protein coding region, especially in the major capsid protein VP1 
for receptor binding as mutations in these amino acids inhibit hemagglutination and 
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Mutations in other viral genes
Mutations also occur in the highly conserved viral regulatory proteins that potentially 
mutations affecting the helicase domain of LTag that might inhibit viral replication 
minor capsid protein genes as point mutations of VP2 and larger deletions of the 
Amino acid mutations detected in neurotropic JCPyV strains and their proposed 
effect on viral pathogenicity. Only most frequently observed VP1 mutations are shown.
VP1
L55F 
Host cell receptor 
recognition region












Abbreviations: VP1, viral protein 1; VP2, viral protein 2; aa, amino acid.
BKPVAN results from reactivated replication of BKPyV persisting in the kidneys. 
Deterioration of immune system, especially of cell-mediated immunity, allows 
more robust replication of BKPyV in the proximal tubular epithelial cells of the 
kidneys leading to cellular detachment and necrosis characterized by interstitial 
of allograft dysfunction and rejection after kidney transplantation and 1.1-10.3% 
of kidney transplant patients develop BKPVAN within a year from transplantation 
organ transplantations, and among kidney transplant patients the allogeneic graft 
22
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Monitoring of BKPyV replication
No prophylactic or curative treatment for BKPVAN is available leaving the monitoring 
of kidney transplant patients as the only option for early intervention and prevention 
of BKPVAN. As prolonged high-level BKPyV viremia and viruria always precedes 
BKPVAN onset, the prospective screening for BKPyV replication in plasma and urine 
of kidney transplant patients every three months up to two-years post-transplantation 
of asymptomatic kidney transplant patients and simultaneous urinary secretion of 
BKPyV viruria BKPyV viremiapositive positive Kidney biopsy positive





PCR for BKPyV DNAuria 
sensitivity 100% 
specificity 92% 
positive predictive value 31%
PCR for BKPyV DNAemia 
sensitivity 100% 
specificity 96% 
positive predictive value 50%
 Screening of kidney transplant patients for BKPyV replication and BKPVAN. 
Diagnosis and intervention
BKPVAN can be presumed if high-level replication of BKPyV in both urine and blood is 
of SV40 LTag or presence of typical cytopathic changes indicative of polyomavirus 
in the kidneys leads to enlarged tubular cells with basophilic viral inclusions and 
sometimes parenchymal scarring due to progressive tubular atrophy and interstitial 
histological classes 1, 2, and 3 characterized by small cytopathic changes, broader 
destruction of kidney tissue, classes 2 and 3 are associated with higher risk for 
multiple tissue sites is recommended to decrease the probability of false negative 
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 Diagnosis of BKPVAN. High-level BKPyV viruria is occasionally accompanied with 




BKPyV DNA load of 
Low-level 
BKPyV viremia
BKPyV DNA load of 
High-level 
BKPyV viremia
BKPyV DNA load of 
-
Kidney biopsy
Viral cytopathic changes 
- -
Abbreviations: BKPyV, BK polyomavirus; BKPVAN, BK-polyomavirus associated nephropathy.
regimen, especially the reduction of antiproliferative drugs and calcineurin inhibitors 
successfully used to treat BKPyV replication in kidney transplant patients, the results 
Risk factors
Several donor- and recipient-related factors have been suggested to increase risk for 
BKPVAN. First, a ten-fold risk is observed if a BKPyV seronegative recipient receives 
The use of some immunosuppressive drugs has been associated with increased 
BKPVAN risk. For instance, the use of tacrolimus and corticosteroids as a maintenance 
therapy together with antithymocyte globulin as an induction therapy may increase 
more important role in the development of BKPVAN.
1.5.2 Seque
stable NCCR structure and mutated strains having a highly variable NCCR architecture. 
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The P, Q, R, and S blocks constitute the TCR containing promoters and enhancer 
causing asymptomatic primary infections are mostly detected in immunocompetent 
individuals as well as in immunosuppressed individuals without BKPVAN indicating 
of BKPyV is determined by the NCCR containing multiple binding sites for host cell 
transcription factors expressed in the kidneys, such as Sp1, NF-1, NFAT, AP-1, and 
mutations seem not alter viral pathogenicity. These strains are therefore called 
Within the organism, major rearrangements, duplications, and deletions in the 
BKPyV NCCR mutations in the development of BKPVAN remains elusive; although 
mutated BKPyV NCCR regions are frequently detected in urine, plasma, and 
for the development of BKPVAN. Further, BKPyV strains with mutated NCCR are also 
 Structure of archetype BKPyV NCCR region. The NCCR can be divided into blocks 
constitute the TCR containing promoters and enhancer elements for the viral gene expression. 
The major capsid protein VP1
Active replication of BKPyV may sometimes lead to accumulation of mutations in 
the VP1: BKPyV strains with mutated VP1 are found in urine, plasma, and kidney 
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73, and 77, have been shown to alter the binding of BKPyV to the host cell receptor 
of BKPVAN remains to be established.
Mutations in other viral genes
Less is known about the impact of mutations in other viral genes in the development 
of BKPVAN. Occasionally mutations in the origin-binding domain of LTag are 
been associated with mutations located in the agnoprotein or minor capsid proteins 
VP2 and VP3 of BKPyV. 
Amino acid mutations detected in BKPyV strains associated with BKPVAN. Only most 









Host cell receptor 
recognition region
Alteration of host cell 
receptor binding
Large T antigen Q150H Origin binding domain Unknown
Abbreviations: VP1, viral protein 1.
Rarely, nephropathy may be caused by lytic infection of JCPyV in the kidneys; to date, 
Currently monitoring of kidney transplant patients for JCPVAN is not recommended 
histopathological changes characteristic for nephropathy and a positive JCPyV LTag 
staining of the kidney tissue are cornerstones in JCPVAN diagnosis. Reduction of 
for JCPVAN are unknown, but similar to BKPVAN, male gender, acute rejection 
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techniques available from 2005 onwards. They have for the most part replaced the 
a chain termination method for sequencing, and electrophoresis for amplicon 
a decade and cost approximately 3 billion dollars. Today, the same can be achieved 
thousands to billions of parallel, spatially separated sequencing reactions producing 
thousands to millions of short sequence reads in a single machine run.
All MPS techniques consist of library preparation, sequencing, and data analysis 
into short-read and long-read sequencing techniques with maximum sequence read 
variation associated with various clinical manifestations including single nucleotide 
alterations. Whole genome sequencing allows the investigation of all mutations within 
an individual genome while whole exome sequencing is used to study protein coding 
MPS techniques have also proven useful in transcriptomics and epigenomics of all 
eukaryotes and they are employed to study DNA-protein interactions by chromatin 
detailed characterization of genomic organization and biological functions taking 
place within a single cell. Further, single cell sequencing of circulating tumor cells 
has enabled investigation of their role in the metastasis formation of for instance 
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technologies. Of note, the duration of sequencing, read length, and maximum output depends 











Illumina Synthesis 1-3 d <1
Substitutions, 
biases
SOLiD Synthesis 10 d 240 0.01 AT bias





















SMRT, single-molecule real-time sequencing.
Short-read sequencing
Short-read sequencing techniques produce sequence reads with a size of few 
step to increase the signal-noise ratio as they are not sensitive enough to detect 
signal from an individual template molecule. Short-read sequencing techniques 
, 
problematic due to short sequence read length of Illumina sequencing, and reverse 
. 
Second, the detection of Ion Torrent sequencing is based on the release of a proton 
DNA polymerase has been replaced by DNA ligase; although being prone to AT bias, 
SOLiD sequencing can distinguish sequence polymorphism from sequencing error as 
Advantages of short-read sequencing techniques include low error rate, fast 
processing, and high-throughput. The high accuracy of short-read sequencing is due 







Nanopore have many advantages over the short-read sequencing techniques: both 
sequencing, where DNA polymerization can be visualized real-time in a base-pair 
SMRT wells with zero-mode waveguide detectors for the detection of incorporated 
ligated to both ends of a template molecule to generate a SMRTbellTM template; 
this allows the polymerase to sequence single template molecule multiple times 
. Pacbio SMRT 
are randomly distributed and do not accumulate at the ends of sequence reads, the 
Oxford Nanopore sequencing, the template molecule is allowed to move through 
templates up to hundreds of thousands of base pairs in size can be sequenced by 
indels, substitutions, and homopolymers pose a problem for Oxford Nanopore 
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sequencing, the polymerase reads a single template molecule multiple times generating 
a polymerase read consisting of multiple subreads that can be used to produce a circular 
Both short- and long-read sequencing techniques require a template processing 
step prior sequencing. Library preparation consists of mechanic or enzymatic 
fragmentation of template molecule, cleaning, end repair, and adapter ligation steps. 
Adaptors may include molecular barcodes to allow sequencing of different samples 
of template to the surface of the well, and recognition sites for the polymerase. To 
ensure data quality and correct interpretation of the results, special care is required 
in all these steps. Challenge during library generation is to increase the amount of 
products, such as host-derived DNA.
biologically meaningful results. Data analysis includes many bioinformatics processes 
reads, and removal of adapter sequences and duplicate reads to improve the accuracy 
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such as primers, nucleic acid extraction, library preparation, and PCR can affect the 
analysis. Errors in sequence data can be generated by signals from nearby clusters 
MPS has increased the diagnosis of previously undiagnosed infectious diseases 
and is currently being adapted into routine virological diagnostics. High coverage 
allows the investigation of viral populations and low-abundance variants in microbial 
sequencing seems feasible in routine diagnostics as it is cheaper and less time-
consuming than long-read sequencing. However, contaminating host sequences 
targeted enrichment methods, such as probe-based enrichment, are used to increase 
the amount of target sequence. MPS can be used to detect minor populations of 
drug-resistant HIV strains and to identify pathogens in diseases of unknown origin 
Currently used diagnostic tests such as PCR rely on the prior knowledge of 
a pathogen. Although MPS-based diagnostic tests currently available cannot yet 
provide as fast turn-around time as real-time PCR, they have decreased dramatically 
the amount of original material needed for pathogen detection and enabled studies 
of non-cultivable microorganisms. One advantage of MPS-based diagnostic tests 
is the ability to simultaneously analyze several genomic regions in a single test. 
Faster library preparation and sequencing, more user-friendly data analysis, and 
clear guidelines for validation are, however, needed in order to improve the feasibility 
of MPS in virological diagnostics. MPS-based diagnostic tests are currently being 
implemented in many diagnostic laboratories worldwide.
Many ethical issues need to be considered before MPS techniques can be 
implemented in routine diagnostics. The huge amount of sequence data generated 
by MPS techniques requires computational power for storage, management, and data 
processing. A lot of the obtained information is unintended, and that raises concern 
about how and whether to use the data or store them for future purposes. European 
clinical laboratories have agreed that only data that has been cleaned from human 
sequences can be shared. Importantly, data sharing is crucial in order to improve 
bioinformatics tools used in the data analysis and to ensure similar results between 
different laboratories. Also an issue of discussion is the balance between high 
quality data and reasonable sequencing costs which are strongly affected by higher 
sequencing coverage and depth. The cost of MPS will continue to drop in the future 
and the cost reduction should be weighed against the quality of a sequence as higher 
coverage does not necessarily mean better quality of a sequence data. Despite ethical 
challenges associated with the use of MPS in diagnostics, the high-throughput and 





The aim of this thesis was to uncover how JCPyV and BKPyV sequence variation 
contributes to disease pathogenesis. The detailed characterization of viral 
populations associated with the development of polyomavirus-associated diseases, 
such as PML and polyomavirus-associated nephropathy, has been partly hindered 
MPS techniques, the role of mutations within the viral genome in the pathogenicity 
of JCPyV and BKPyV and in the development of PML, BKPVAN, and JCPVAN was 
studied.
• To characterize PML-associated mutations originating from individual 
• To study whether mutations within the viral genome, especially in the NCCR, 
• To investigate the role of BKPyV TCR mutations in the development of BKPVAN 




This section summarizes the sample material, methods, and clinical characteristics 
of patients used in this thesis. The reader is kindly instructed to have a look at the 
design.
3 had no prior immunosuppressive medication or condition apart from type 2 diabetes.
All patients demonstrated neurological symptoms characteristic to PML. 
Severe headache accompanied with vision disturbances were observed in patient 1 
and brain magnetic resonance imaging revealed lesions in the right and left occipital 
lobes, and right frontal subcortical lobes. High amount of JCPyV DNA was detected 
PML diagnosis. Patient 2 had neurological symptoms including tiredness, apraxia 
of both hands, and visual impairment. White matter lesions in the temporo-occipital 
delirium, and brain computed tomography showed infarct in the right frontal lobe. The 
symptoms rapidly progressed into epileptic seizures, cognitive decline, and speech 
apraxia accompanied with lesions in the both frontal lobes, right occipital lobe as well 
as both sides of the cerebellum and pons. High amount of JCPyV DNA was detected 







































To study the role of mutations within JCPyV genome in severe kidney diseases, urine 
samples of twenty patients who had undergone a kidney transplantation at Helsinki 
consisted of cyclosporine or tacrolimus, mycophenolate and steroids, and patients 
with higher immunological risk received also an induction therapy with basiliximab. 
All patients had stable allograft function with the mean plasma creatinine level of 133 
 Clinical characteristics of stable kidney transplant patients with JCPyV viruria.
(μ
(μ
4 Female 149 None 104
5 Female 141 None 234
Male 131 None 131
7 Male 18 104 None
8 Male 71 None
9 Male 48 119 None
10 Male 47 235 None 235
11 Male 19 123 None 123
12 Male 52 159 None 147
13 Female 149 None 85
14 Male 21 185 Minor graft 
dysfunction
152
15 Female 32 70 None 112
Male 73 202 None 149
17 Male None 107
18 Male None
19 Female 17 None 70
20 Male 2 42 Pollakisuria, 
pyuria
53
21 Male 47 118 None 131
22 Male 49 134 None 131
23 Male 50 None 100
Abbreviations: KTx, kidney transplantation.
Also included were four urine and three plasma samples from one kidney 
13
samples 1 and 2, were taken after the diagnosis of JCPVAN. The patient has been 
transplantation at Helsinki University Hospital receiving a cadaveric kidney allograft. 
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not detected in plasma or urine. The diagnosis of JCPVAN was based on the positive 
SV40 LTag immunoperoxidase staining of multiple biopsies and positive JCPyV DNA 
but negative BKPyV DNA by PCR. Retrospectively the patient was shown to be JCPyV 
after transplantation; anti-BKPyV antibodies remained negative at all times. Despite 
reduction of immunosuppression, the kidney allograft was lost 27 months after the 
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borderline acute 
Positive

















To assess the role of BKPyV TCR variation in the development of BKPVAN, plasma 
samples per patient, 53 in total, 






and was successfully treated in all patients with reduction of immunosuppressive 
regimen. Nine patients experienced allograft dysfunction indicated by a decrease 
and 24 lost the allograft due to antibody-mediated rejection. Two kidney transplant 
patients with stable allograft function and no BKPyV viremia or viruria detected in 
routine screening were included as controls in study III.
 Clinical characteristics of kidney transplant patients with BKPyV viremia. Only the 
sampling date for the sample used for characterization of BKPyV TCR is shown.
III 1 Male Stable 55 Stable
2 Male Stable 0 Stable
3 Male 72 Stable 0 Stable
4 Female 47 Stable 219 Stable
5 Male 54 0 Stable
Male 45 Stable 47 Rejection
7 Male 9 Stable
8 Male 45 Stable 0 Stable
9 Female 71 Stable 0 Stable
IV 10 Male 58 Stable 0 Stable
11 Male 59 Stable 77 Stable
12 Male 23 Stable 0 Stable
13 Male 72 Stable 71 Stable
14 Male 52 Stable 0 Stable
15 Male 27 Stable 28 Stable
Male 0 Stable
17 Male 59 28 Stable
18 Female 45 Stable 22 Stable
19 Female 39 Stable 78 Stable
20 Female 90 Stable
21 Male 14 Stable
22 Female 58 131 Stable
23 Male 44 148 Stable
24 Female 49 14 Rejection
Abbreviations: KTx, kidney transplantation; BKPyV, BK polyomavirus.
















to amplify every nucleotide of the genome, the primers were designed to the adjacent 
regions within the LTag gene. The PCR reactions contained 1x Q5 reaction buffer 
agarose gel.
Experimental design
The SMRT library preparation and sequencing were done according to the 
sites, and oxidation damage were repaired. For library generation, blunt ends were 
generated at both ends of each amplicon followed by the ligation of hairpin-loop 
adapters to create a SMRTbellTM template. Failed ligation products were removed by 
exonuclease treatment. Sequencing was performed using PacBio RS II System and 
C4 chemistry. For sequence analysis, tools available in the SMRT Analysis Software 
with polymerase reads containing 5 or more full passes of complete JCPyV genome 





The sequencing libraries were constructed according to the manufacturer’s 
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strands of an amplicon.
The in-house pipeline used for the sequence analysis is depicted in . Shortly, 
adapter sequences were removed from read pairs and reads were trimmed using 
discarded. The FLASH tool was used to combine read pairs containing both forward 
and reverse primer sequences. For clustering, the DNACLUST tool with identity cut-
MEM mapping tool and the Tablet tool was used for alignment visualization. The 
cut-off value for cluster size was set at 1,000 sequences comprising >90% of all 
sequences per sample. The cluster reference sequences were used to characterize 
BKPyV TCR regions present in a sample using the TCR of archetype BKPyV WW strain 
Adapter removal





- minimum read length of 50 bp 
- PHRED quality score of 30 
- no reads with N bases
- FLASH tool 
- reads with FOR and REV primers
- identity cut-off value of 97.5% 
- cluster size of 1000 sequences
- BWA-MEM mapping 
- Tablet vizualization




miR-B1-5p, and bkv-miR-B1-3p, and cel-miR-39-3p. The reverse transcription reaction 
contained 10 ng of total RNA, 1x reverse transcription buffer, 0.25 mM of each dNTP, 
1x reverse transcriptase primer, 49.95 U MultiScribeTM reverse transcriptase enzyme, 
according to the manufacturer´s instructions. The microRNA qPCR reaction contained 
accepted range of variation between replicates have not been established. Here, the 
or more of the replicates. For positive samples, a normalized mean threshold cycle 
mean Ct value of cel-miR-39-3p from the mean Ct values of both viral microRNAs. 
To compare microRNA expression between symptomatic kidney transplant patients 
calculated according to the 2
40
Results and Discussion
4 RESULTS AND DISCUSSION
Mutations frequently occur within the genome of human polyomaviruses that might 
alter viral pathogenicity. Mutations within the JCPyV genome are prerequisite for 
few studies on the matter currently exist. The mechanisms behind the emergence of 
mutated strains as well as the exact content of mutations needed for the development 
of PML and polyomavirus-associated nephropathy remain still elusive. 
In this thesis, the role of sequence variation of JCPyV and BKPyV in the 
pathogenesis of PML and polyomavirus-associated nephropathy was investigated 
Replication of reactivated JCPyV in the brain glial cells may lead to destruction of 
but the exact content of mutations needed for the disease onset is elusive. Extremely 
rarely reactivation of JCPyV replication in the kidneys can result in the lytic infection of 
of this condition, little is known about the role of viral genetic variation in JCPVAN 
pathogenesis.
In this thesis, the role of mutations within the JCPyV genome in the development 
of the rare PML and JCPVAN diseases was investigated by characterizing all 
all patients and they died within months from diagnosis. Also included were urine 
The patient with JCPVAN eventually lost the graft due to the primary JCPyV infection 
and antibody-mediated rejection.
In order to amplify and characterize a complete JCPyV genome, a qualitative 
PCR method with forward and reverse primers binding to the adjacent regions 
was established. The aim was to sequence every nucleotide in the JCPyV genome 
using PacBio SMRT sequencing and characterize complete JCPyV strains in single 
sequence reads without bias of assembling smaller sequence fragments. 
characterization of JCPyV strains were obtained from all PML patients due to the 
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. The subreads were used to generate consensus circular 
sequences for all samples using the Long Amplicon Analysis tool: three different 
consensus circular sequences representing complete JCPyV sequences 1.1, 1.2, and 
1.3 with subread coverages of 38, 159, and 142, respectively, were obtained from 
patient 1. The circular consensus sequences of patients 2 and 3 represented both 
consensus sequences from PML patient 1 were interpreted as low-quality noise 
sequences generated during sequencing.
Sequencing of complete JCPyV genomes from the urine of kidney transplant 
complete JCPyV sequences were obtained from the plasma.
Summary of sequence data obtained from PML patients, stable kidney transplant 
for twenty stable kidney transplant patients are shown. For more detailed information, see 
Supplementary Table 1.
I 1 CSF 937,900 1.1 38 5,127
1.2 159 5,233
1.3 142 5,285
2 CSF 32,537 2 >500 5,151
3 CSF 25,537 3 >500
II 4-23 Urine 18,873 4-23 >500
24 Plasma 1 <400 1,842
Plasma 2 <400 3,529
Plasma 3 <400
Urine 1 5,008 24.1 >500
Urine 2 24.2 >500
Urine 3 5,875 24.3 >500





containing promoters and enhancer elements for early and late viral gene expression. 
strains with small TCR point mutations and neurotropic strains with larger TCR 
increasing the number of transcription factor binding sites favouring viral replication 
, 
the most variable viral gene region. The architecture of NCCR was similar, although 
not identical, between different JCPyV strains, and the length varied both between 
Of note, patient 1 with multiple neurotropic strains had an exceptionally rapid onset 
of PML. Although our cohort is limited, it seems that the content of mutations within 
the JCPyV genome rather than presence of multiple viral strains is important for PML 
pathogenesis.
rearrangements were detected in the strains 1.1, 1.2, and 1.3 of PML patient 1 indicating 
that they could be derivatives of a single NCCR region. Prolonged clinical picture of 
this patient may have enabled the emergence of multiple neurotropic strains. Based 
on the results, the deletion of archetypal D block, harboring binding sites for glial 
mutation was observed in the neurotropic strain of PML patient 2. Moreover, either 
partial or complete duplications seem to take place in the archetypal A, B, C, E, and F 
blocks of neurotropic strains; these blocks harbor also binding sites for Spi-B and Sp1 
indicating that the loss of binding sites in one block could be complemented by an 
increase in the number of binding sites in other blocks. No direct correlation between 
2 with rapid clinical course had only an archetype-like strain with 10-bp deletion in the 
the disease pathogenesis. Finally, single nucleotide point mutations were detected 
mutations remains to be determined. 
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Parenthesis indicate a truncated archetypal sequence block.
NCCR TCR 






2 2 374 Archetype-like
3 3 397 Neurotropic
Abbreviations: NCCR, noncoding control region; TCR, transcriptional control region.
alignment, the multiple sequence alignment tool Kalign and multiple sequence alignment 
NCCR rearrangements of neurotropic and archetype-like JCPyV strains of 
PML patients affected the number of binding sites for host cell transcription factors 
; Liimatainen H. 
increased the binding sites for NF-1, AP-1, p53, and Tst-1. These factors have been 
shown to increase viral replication in the susceptible host cells: Tst-1 increases viral 
early and late gene expression, and AP-1 regulates viral replication by binding to LTag 
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 Potential transcription factor binding sites in the TCR of PML-associated JCPyV 






(2) (0) (5) (1)
1.1 2 1 1 2 0 4 1
1.2 3 1 1 3 0 7 2
1.3 3 2 2 3 1 1
2 2 2 1 2 0 5 1
3 3 1 1 3 0 4 1
AP-1, activator protein 1; Egr-1, early growth response protein 1; Spi-B, hematopoietic transcription 
factor; p53, tumor suppressor protein p53.
within the JCPyV genome are associated with the development of JCPVAN. In the 
present work, archetype JCPyV was found dominant both in the urine of twenty kidney 
and 20, 
the reference archetype strain. Archetype JCPyV is thought to cause asymptomatic 
patient 14 with minor graft dysfunction had an archetype-like strain harboring 8-bp 
NF-1 increases the replication of JCPyV in the kidneys remains to be studied. Similar 
deletion has been previously detected in JCPyV strains of stable kidney transplant 





Urine 24.1 384 Archetype
Urine 24.2 384 Archetype
Urine 24.3 384 Archetype




JCPyV strains from urine of twenty kidney transplant patients with stable graft 
function. Patient 14 had minor graft dysfunction and patient 20 experienced pollakisuria and 
pyuria. Truncated archetypal sequence blocks are presented in parenthesis.
NCCR TCR 
4 4 384 Archetype
5 5 384 Archetype
384 Archetype
7 7 384 Archetype
8 8 384 Archetype
9 9 384 Archetype
10 10 384 Archetype
11 11 384 Archetype
12 12.1 384 Archetype
12.2 384 Archetype
13 13 384 Archetype
14 14 370 242 Archetype-like
15 15 384 Archetype
384 Archetype
384 Archetype
17 17 384 Archetype
18 18.1 384 Archetype
18.2 384 Archetype
19 19 384 Archetype
20 20 384 Archetype
21 21.1 384 Archetype
21.2 384 Archetype
22 22.1 384 Archetype
22.2 384 Archetype
23 23 384 Archetype
Abbreviations: NCCR, noncoding control region; TCR, transcriptional control region; bp, base pair.
coding region of patient strains to the corresponding region of the reference genotype 
currently known, and genotypes 1, 2, and 3 are further divided into several genotypes 
and seventeen stable kidney transplant patients with JCPyV viremia belonged to 
genotype 1: subtypes 1A and 1B were detected in nine and ten patients, respectively. 
Results further support the notion that genotype 1 is frequently detected in Europe 
of this patient differed from other PML patients. Of note, a strain of stable kidney 
transplant patient 8 belonged also to the genotype 2B. The genotype 4, dominant in 
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that genotype 4 is rare in Finnish population.
the urine, the differences between strains were observed in the protein coding region 
individual could be a result of co-infection of different strains as suggested for other 
mutations except in patient 12 whose strains differed by a larger, 12-bp deletion in the 
has been observed in the neurotropic strains of PML patients suggesting a role in the 
Mutations leading to amino acid changes within VP1 were characterized in detail 
as mutations in the receptor recognition region of VP1 may enhance the ability of 
regions of patient strains from both PML and kidney transplant patients shared 99% 
the VP1 were more frequent in the archetype and archetype-like strains than in the 
from PML patients had amino acid point mutations located in the HI loop, a part of 
region are necessary for the PML onset. A different HI loop mutation was observed 
not affecting the receptor recognition region of VP1. The neurotropic and archetype-
like strains of PML patients had mutations affecting the HI and BC loops previously 
The strains of stable kidney transplant patients had amino acid point mutations 
stable kidney transplant patients and the archetype strain of patient 14 with minor 
the neurotropic strain of patient 2. Most VP1 mutations, such as S222N detected 
in strains of ten stable kidney transplant patients, were, however, not located in the 
receptor recognition region of VP1. Further, the strain of patient 8 had no VP1 amino 
acid point mutations. The results suggest that mutations within the VP1 occasionally 
occur during viral replication in the kidneys and brain but different mutations may be 
favored due to different biology of these cells.
The archetype strains of the patient with JCPVAN had two mutations affecting 
kidney transplant patients but none of the neurotropic strains of PML patients, now 
region of VP1 occur more frequently in the strains associated with PML than JCPVAN: 
especially mutations within the HI loop seem to have a role in the host cell tropism.
Results and Discussion
Amino acid point mutations within the VP1 of JCPyV strains of PML patients and 
1 PML 1.1 C800T HI
1.2 C800T HI
1.3 C800T HI




3 PML 3 BC
BC
HI
4 KTx 4 None
L158V EF
K345R None




7 KTx 7 BC
None
8 KTx 8 - - -
9 KTx 9 None
L158V EF
K345R None












13 KTx 13 BC
S222N None
14 KTx 14 None
L158V EF
K345R None









17 KTx 17 BC
None
18 KTx 18.1 T128S DE
18.2 T128S DE




20 KTx 20 BC
None









23 KTx 23 BC
None




Abbreviations: PML, progressive multifocal leukoencephalopathy; KTx, kidney transplantation; JCPVAN, 
JC polyomavirus-associated nephropathy; VP1, viral protein 1.
As a major regulatory protein, LTag is a key regulator of viral DNA replication and gene 
alter viral pathogenicity and have a role in the development of PML and JCPVAN. To 
this end, amino acid point mutations within the LTag of JCPyV strains of PML patients 
Of the PML patients, only the neurotropic strains of patient 1 and the archetype-like 
immunocompetent PML patient 3. 
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T357S and the helicase domain mutation K507R were observed in patients 17 and 
18, respectively. Finally, a total of eight stable kidney transplant patients and the 
patient with JCPVAN did not have mutations affecting the functional domains of 
LTag. Mutations in the functional domains of LTag seem to rarely associate with 
the development of PML and never with JCPVAN indicating a different role of LTag 
prolonged immunosuppression, might allow accumulation of mutations within the 
LTag. 
 Amino acid point mutations within the LTag of JCPyV strains of PML patients and 
1 PML 1.1 K507R Helicase
1.2 K507R Helicase
1.3 K507R Helicase
2 PML 2 C1958T None
3 PML 3 - - -
4 KTx 4 C1958T None
5 KTx 5 C1958T None
KTx C1958T None
7 KTx 7 C478T OBD
8 KTx 8 OBD
9 KTx 9 C1958T None
10 KTx 10 None
11 KTx 11 None
12 KTx 12.1 C478T OBD
12.2 C478T OBD
13 KTx 13 C478T OBD
C1958T None
14 KTx 14 C1958T None
15 KTx 15 C478T OBD
KTx C478T OBD
C478T OBD
17 KTx 17 C478T OBD
T357S
18 KTx 18.1 K507R Helicase
18.2 K507R Helicase
19 KTx 19 C1958T None





21 KTx 21.1 C478T OBD
21.2 C478T OBD




23 KTx 23 C478T OBD
C1958T None
24 JCPVAN 24.1-24.4 None
Abbreviations: PML, progressive multifocal leukoencephalopathy; KTx, kidney transplantation; JCPVAN, 
JC polyomavirus-associated nephropathy; LTag, large T antigen. OBD, origin binding domain.
Deterioration of the immune system especially after kidney transplantation may 
predispose to reactivation of BKPyV replication in the kidneys and lead to the 
development of BKPVAN. BKPVAN is a major cause of allograft dysfunction 
rearrangements, deletions, and duplications frequently occur within the BKPyV TCR 
remains still unknown.
In this thesis, the role of mutations within the BKPyV TCR in the development 
of BKPVAN was studied by characterizing BKPyV TCR regions from a total of twenty-
collected while pairs of urine and plasma samples were obtained from two probable 
was to sequence the complete BKPyV TCR in a single continuous read using Illumina 
short-read sequencing.
Paired-end sequencing of complete BKPyV TCR from plasma of nine kidney transplant 
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sample were available for the characterization of BKPyV TCR.
4.2.2 TCR
architecture of TCR: archetype strains having small point mutations within the TCR 
infections are thought to be caused by archetype strains while rearrangements within 
regions from plasma of twenty-four kidney transplant patients with either probable, 
plasma represented archetype TCR; in the plasma of six presumptive BKPVAN and 
23
were located in the binding sites for tumor suppressor protein p53; both NF-1 and p53 
archetype TCR. Rearranged BKPyV TCR regions were also characterized from the 
plasma of two probable BKPVAN patients, three presumptive BKPVAN patients, and 
TCR regions in the probable BKPVAN patients, presumptive BKPVAN patients, and 
cohort size. Most variation in the structure of rearranged TCR regions was observed 
patient groups. Increased viral replication in the kidneys due to BKPVAN might allow 
accumulation of mutations within the archetypal TCR and subsequent development 
of mutated strains. Most frequent TCR mutation in all three patient groups was a 
partial deletion of archetypal Q and R blocks harbouring binding sites for transcription 
partial and complete duplications of P and Q blocks containing binding sites for viral 
the results, deletions and duplications in the archetypal P, Q, and R blocks frequently 




 BKPyV TCR regions in plasma of kidney transplant patients with or without 
graft dysfunction at sampling.
TCR 
10 Probable BKPVAN 10.1 234 P-Q-R-S Archetype 98.17
10.2 207 Rearranged 1.93
11 Probable BKPVAN 11.1 233 P-Q-R-S Archetype
11.2 188 Rearranged 3.98
3 Presumptive BKPVAN 3 233 P-Q-R-S Archetype 99.90
9 Presumptive BKPVAN 9.1 234 P-Q-R-S Archetype
9.2 315 Rearranged 2.10
12 Presumptive BKPVAN 12 233 P-Q-R-S Archetype 99.97
13 Presumptive BKPVAN 13.1 233 P-Q-R-S Archetype 98.90
13.2 279 Rearranged 0.97
14 Presumptive BKPVAN 14 233 P-Q-R-S Archetype 99.97
15 Presumptive BKPVAN 15 233 P-Q-R-S Archetype 99.97
Presumptive BKPVAN 233 P-Q-R-S Archetype 99.81
17 Presumptive BKPVAN 17 234 P-Q-R-S Archetype 98.84
18 Presumptive BKPVAN 18 233 P-Q-R-S Archetype 98.82
19 Presumptive BKPVAN 19.1 233 P-Q-R-S Archetype
19.2 184 Rearranged 0.89
19.3 215 Rearranged 0.51
1 1.1 233 P-Q-R-S Archetype
1.2 331 Rearranged 3.0
2 2.1 233 P-Q-R-S Archetype 97.20
2.2 175 Rearranged 2.70
4 4.1 234 P-Q-R-S Archetype
4.2 275 Rearranged 2.50
5 5.1 234 P-Q-R-S Archetype 89.80
5.2 180 Rearranged 5.90
5.3 283 Rearranged 1.20
5.4 317 Rearranged 1.20
234 P-Q-R-S Archetype 83.90
283 Rearranged 15.90
7 7.1 234 P-Q-R-S Archetype
7.2 192 Rearranged 22.40








20.4 208 Rearranged 5.19
20.5 232 Rearranged 2.88
225 Rearranged
20.7 234 P-Q-R-S Archetype
21 21.1 234 P-Q-R-S Archetype 57.11
21.2 185 Rearranged 4.75
21.3 208 Rearranged 4.38
22 22.1 233 P-Q-R-S Archetype
22.2 141 Rearranged 3.32
22.3 152 Rearranged 3.12
22.4 Rearranged 2.85
23 23.1 233 P-Q-R-S Archetype
23.2 184 Rearranged
23.3 Rearranged 10.81
23.4 173 Rearranged 5.41
23.5 145 Rearranged 5.19
215 Rearranged 4.28
23.7 113 Rearranged
24 24 234 P-Q-R-S Archetype 99.42
Abbreviations: BKPVAN, BK polyomavirus-associated nephropathy; BKPyV, BK polyomavirus; TCR, 
transcriptional control region.
urine and plasma of a single patient were always 100% identical indicating that robust 
viral replication in the kidneys might enable spreading of BKPyV strains from the 
BKPVAN, archetype TCR predominated in the urine contrary to plasma where multiple 
rearranged strains were detected. In one presumptive BKPVAN patient a rearranged 
TCR regions were not identical in the plasma and urine of a single patient, similar 
deletions of archetypal Q and R blocks were found. 
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 BKPyV TCR regions in urine of kidney transplant patients with or without 
graft dysfunction at sampling.
BKPVAN TCR 
10 Probable BKPVAN 10.1 234 P-Q-R-S Archetype 97.19
10.2 184 Rearranged
11 Probable BKPVAN 11 233 P-Q-R-S Archetype 99.72
12 Presumptive BKPVAN 12 233 P-Q-R-S Archetype 99.87
13 Presumptive BKPVAN 13.1 233 P-Q-R-S Archetype 98.72
13.2 144 Rearranged 0.74
14 Presumptive BKPVAN 14 233 P-Q-R-S Archetype 98.1
15 Presumptive BKPVAN 15 233 P-Q-R-S Archetype
Presumptive BKPVAN 233 P-Q-R-S Archetype
17 Presumptive BKPVAN 17.1 234 P-Q-R-S Archetype 92.37
17.2 185 Rearranged 3.88
18 Presumptive BKPVAN 18 233 P-Q-R-S Archetype 98.82
19 Presumptive BKPVAN 19.1 233 P-Q-R-S Archetype
19.2 184 Rearranged 0.89








21 21.1 234 P-Q-R-S Archetype 73.22
21.2 185 Rearranged
21.3 208 Rearranged 4.58
22 22 233 P-Q-R-S Archetype 98.77
23 23.1 233 P-Q-R-S Archetype
23.2 215 Rearranged 17.33
23.3 184 Rearranged 7.97
23.4 113 Rearranged
23.5 145 Rearranged 5.18
Rearranged 4.78
23.7 173 Rearranged 3.98
24 24 234 P-Q-R-S Archetype 99.71




The number of binding sites for host cell transcription factors within the TCR 
BKPVAN altered the number of transcription factor binding sites for Sp1, NF-1, NFAT, 
importance in viral DNA replication and gene expression. The amount of binding sites 
blocks. However, no correlation in the viral load and the amount of binding sites for 
NF-1 or Sp1 within the rearranged TCR regions was observed further indicating the 
predominance of archetype strains in the urine and plasma. The number of binding 
remained unchanged in most patients. No clear association between the number of 
transcription factor binding sites and disease status was established.
 The number of transcription factor binding sites within the rearranged BKPyV 
TCR. For comparison, the number of binding sites for each transcription factor in the TCR 







13 Probable BKPVAN Urine 1 2 5 1 1
Plasma 1 3 1 1
14 Probable BKPVAN Plasma 0 2 4 2 1
9 Presumptive BKPVAN Plasma 2 2 8 2 3
11 Presumptive BKPVAN Urine 1 1 4 1 1
Plasma 2 4 2 3
17 Presumptive BKPVAN Urine 1 3 4 1 2
19 Presumptive BKPVAN Urine 1 3 5 1.50 2
Plasma 1 3 5.50 1 2
1 Plasma 2 2 8 3 3
2 Plasma 1 1 4 1 2
4 Plasma 2 1 7 2 2
5 Plasma 2.33 2.33
Plasma 2 2 7 2 2
7 Plasma 1 1 1 2
20 Urine 1.29 3.14 5.14 1.71 2.14
Plasma 2.93 1.43 2
21 Urine 1 2 4.38 1 1.88
Plasma 1 1.70 4.30 1 1.80
22 Plasma 1 4.20 1.33 1.47
23 Urine 1.08 5.23 1.33 1.85
Plasma 1.13 2.25 1.25 1.75




BKPyV encodes two microRNA molecules, bkv-miR-B1-5p and bkv-miR-B1-3p, that 
Thus, BKPyV-encoded microRNAs may affect viral pathogenesis and subsequently 
the association of BKPyV TCR mutations and the expression of BKPyV-encoded 
levels from a total of 53 plasma samples were measured. Plasma samples of two 
adult kidney transplant patients with stable graft function and no evidence of BKPyV 
viremia or viruria were used as controls. The collection of more control patients was 
hindered by the fact that 35-57% of kidney transplant patients experience BKPyV 
controls due to the fact that they probably had encountered BKPyV infection which 
BKPVAN patients had on average 8.7-fold and 8.9-fold higher 5p and 3p microRNA 
expression than the controls, respectively. The presumptive BKPVAN patients had 
statistical analysis. Due to the nucleotide identity of JCPyV and BKPyV 3p microRNAs 
have been affected by JCPyV-encoded microRNAs present in the plasma.
The expression of BKPyV microRNAs is regulated by the late promoter within 
the NCCR, implying that NCCR mutations might affect the expression levels of 
BKPyV predominating in the plasma suggesting that viral 5p microRNA controls the 
both archetype and rearranged strains in the plasma, both viral microRNA expression 
and BKPyV DNA load were increased indicating that even minor populations of 
high 5p microRNA expression.
Results and Discussion
 BKPyV microRNA expression in the plasma of kidney transplant patients with 
sampling. Fold changes of BKPyV microRNA expression were calculated comparing the 
normalized Ct values of both controls to the normalized Ct values of kidney transplant patients. 
Correlation between BKPyV microRNA expression and BKPyV DNA load was calculated using 
the Excel Correl function.
1 P-Q-R-S Archetype 5.0 18.4 -0.19 -0.24
Rearranged
2 P-Q-R-S Archetype 19.1 -0.73 -0.84
Rearranged
3 Presumptive BKPVAN P-Q-R-S Archetype 1.2 3.9 -1.00 1.00
4 P-Q-R-S Archetype 2.0 5.2 -0.99 -0.98
Rearranged




 P-Q-R-S Archetype 1.7 9.3
Rearranged
7 P-Q-R-S Archetype 3.0 -0.94 0.44
Rearranged
8 P-Q-R-S Archetype 0.9 2.9 1.00 1.00
9 Presumptive BKPVAN P-Q-R-S Archetype 5.0 -0.44 -0.39
Rearranged
Abbreviations: BKPVAN, BK polyomavirus-associated nephropathy; TCR, transcriptional control region.
PML is a neurodegenerative brain disease with poor prognosis, and even if the disease 
progress could be halted the damage is irreversible resulting in various neurological 
that mutations within the NCCR are necessary for PML onset. In one patient multiple 
neurotropic strains develop before PML onset or as a result of robust viral replication 
in the brain remains to be determined. It seems that changes in the number of binding 
play a role in the pathogenesis as all PML-associated strains had changes in the 
number of binding sites for Spi-B, known to increase JCPyV replication in the brain 
Reactivation of JCPyV replication in the kidneys can extremely rarely lead to 
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archetype JCPyV strains in the urine of immunosuppressed and immunocompetent 
kidneys. In the present work, only archetype JCPyV was established in the urine 
JCPVAN indicating that mutations within the viral genome are not necessary for the 
pathogenesis of JCPVAN. Interestingly, the JCPVAN patient was previously shown to 
allow the replication of persisting archetype JCPyV in the kidneys ultimately leading 
to JCPVAN onset. This is in contrast with PML, where mutations within the JCPyV 
genome are required for the disease onset. Different roles of viral sequence variation 
in the pathogenesis of PML and JCPVAN could be due to different replication 
conditions in kidney and brain glial cells. Further, in case of JCPVAN, viral mutations 
seem not enhance viral transmission within the organism as JCPyV viremia is rarely 
The role of viral mutations in the pathogenesis of BKPVAN seems similar to 
the major viral population in the plasma and urine of all but one kidney transplant 
patient with or without clinical and histological evidence for BKPVAN. Contrast to 
the archetype-like strain of one PML patient, the archetype-like strain associated with 
BKPVAN had decreased number of binding sites for transcriptional-activator NF-1 
suggesting either that JCPyV and BKPyV have different host cells in the kidneys or 
different transcription factors regulate their replication in a same cell type. Similar to 
were detected in the urine and plasma of patients with or without BKPVAN; robust 
viral replication in the kidneys may allow spreading of viral particles via the systemic 
circulation. Further, mutated BKPyV strains, albeit in minority, might have altered 
pathogenic capacity due to enhancement of viral microRNA expression.
No curative or prophylactic treatment for PML or polyomavirus-associated 
at risk as the only option. At present, the only way to evaluate PML risk is to screen for 
PML. More accurate diagnostic methods for monitoring of JCPyV reactivation is thus 
needed. Although kidney transplant patients are routinely monitored for the presence 
monitoring of kidney transplant patients for JCPVAN is currently recommended due 
nature of this thesis, it seems that monitoring for the emergence of neurotropic 
JCPyV strains could be used to predict the development of PML. On the contrary, the 
presence of mutated BKPyV strains seems not be associated with BKPVAN onset but 
they are rather a by-product of robust viral replication in the kidneys. 
With advances in novel molecular techniques, such as MPS, our knowledge 
on human polyomaviruses is only expected to increase. Apart from prolonged 
immunosuppression, predisposing factors of human polyomavirus-associated 
diseases remain largely unresolved. MPS enables extremely detailed characterization 
of viral strains present in a biological sample providing a novel way for investigating 
the biology of human polyomaviruses that is important in order to improve the 




Human polyomaviruses are important human pathogens causing various clinical 
manifestations almost exclusively in immunosuppressed individuals. In the last 
decade, the number of known human polyomaviruses has expanded mostly owing to 
the establishment of highly sensitive MPS techniques allowing the characterization 
of very small viral populations present in a sample. Further, the PML risk associated 
with the use of some novel biological drugs has increased the interest in the biology 
of JCPyV, discovered already in the 1970s. This thesis summarizes the studies 
investigating the sequence variation of JCPyV and BKPyV in association with PML, 












Sequence variation of JCPyV and BKPyV and its role in the pathogenesis of PML, 
JCPVAN, and BKPVAN.
In this work, complete JCPyV genomes of PML patients and kidney transplant 
characterized. In agreement with previous studies, neurotropic strains harboring 
rearrangements within the NCCR were shown to associate with PML; moreover, 
PML. The presence of archetype-like strain in one patient indicated, however, that 
NCCR rearrangements are not always necessary for the disease onset and could 
be compensated with mutations occurring in the protein coding region such as in 
the major capsid protein VP1. In contrast to PML, mutations within JCPyV genome 
seem not necessary for the development of JCPVAN since archetype or archetype-
like JCPyV strains dominated in urine of all kidney transplant patients. Other factors, 
of this kidney disease. 
To study the role of viral mutations in the development of BKPVAN, BKPyV TCR 
regions of kidney transplant patients with or without clinical or histological evidence 
of BKPVAN were characterized. Similar to JCPVAN, archetype BKPyV predominated 
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in the kidneys due to immunosuppression could allow accumulation of mutations 
within the NCCR and emergence of rearranged strains that, even as a minority, could 
play a role in the viral pathogenesis by affecting e.g. the expression of BKPyV-encoded 
microRNAs.
PML and polyomavirus-associated nephropathy are severe, even fatal, chronic 
diseases. No prophylactic or curative treatment for these diseases currently exists 
leaving the monitoring of patients as the only option. This thesis has increased the 
knowledge on the role of sequence variation in the pathogenicity of JCPyV and BKPyV 
and development of PML, BKPVAN, and JCPVAN. The results provide new information 
to be used in the establishment of more sensitive and accurate diagnostic methods 




many. This thesis was carried out in the Department of Virology and Immunology, 
Helsinki University Hospital Laboratory, and Department of Virology, Faculty of 
Medicine, University of Helsinki. I want to acknowledge Director Maija Lappalainen 
excellent facilities for my research work.
First and foremost, I want to thank my supervisor, Docent Eeva Auvinen. I admire 
your endless enthusiasm for science, in particular for virology, that has served as 
an inspiration for this thesis. Thank you for your support, excellent advices, and 
for giving me the freedom to develop as an independent researcher. Thank you for 
believing in me in times when I myself have not. The former group member, PhD Elina 
Virtanen is warmly thanked for her support, both mental and science-related, during 
this thesis work. Thank you for all those long but fruitful brainstorming sessions. My 
thesis committee, Emeritus Professor Veijo Hukkanen, Professor Petri Auvinen, and 
Docent Sisko Tauriainen are also acknowledged for providing critical insights and 
support during this research work.
I want to warmly thank all our excellent collaborators who have been participating 
in this thesis work. I want to acknowledge all members of the DNA genomics and 
sequencing lab, at the Institute of Biotechnology, University of Helsinki for their 
excellent assistance. Special thanks go to MSc Pia Laine and Laboratory Engineer 
Lars Paulín for their endless support and guidance in the sequencing-related matters. 
the Department of Virology and Immunology, Helsinki University Hospital Laboratory 
are warmly thanked for their aid in countless practical issues. I want to also express 
my gratitude to my dear PMS lab members, Kati Hokynar, Anu Kaitonen, and Satu 
Hänninen for surrounding me with cheerful, and sometimes crazy, atmosphere. 
Last but by far not the least, I want to thank my family for being always there for 
me. I am really fortunate to have you all in my life. I am also eternally grateful for my 
beloved husband, Niclas. Thank you for your endless patience and support during 
this project. I love you.
This thesis was funded by Juhani Ahon Lääketieteen Tutkimussäätiö, Munuaissäätiö, 





Characteristics of PacBio long-read sequence data obtained from 
three PML patients, twenty asymptomatic kidney transplant patients, and one kidney transplant 
CCS 
I 49,293,033 1.1 38 713.91 5,127 98.828
1.2 159 1,142.55 5,233 99.955
1.3 142 1,012.33 5,285 99.994
32,537 99,154,011 2.1 >500 5,151 99.994
25,537 83,007,590 3.1 >500 99.994
II 4.1 >500 2,933.94 99.994
17,175 53,137,802 5.1 >500 3,214.79 99.994
>500 99.994
18,022 54,257,074 7.1 >500 3,201.02 99.994
14,770 8.1 >500 99.994
9.1 438 2,431.03 99.981
10.1 >500 99.994
11.1 >500 99.994
22,054 12.1 190 99.974
12.2 2,191.28 5,151 99.994
82,484,521 13.1 >500 4,557.91 99.994
25,990 81,711,239 14.1 >500 3,924.82 5,149 99.994
71,859,179 15.1 >500 99.994
27,911 82,797,459 203 2,385.37 99.994
297 99.984
51,942,003 17.1 >500 3,281.13 99.994
82,484,521 18.1 214 99.993
18.2 99.994
14,077 43,397,292 19.1 432 99.994
20.1 >500 3,885.83 99.994
21.1 239 2,912.89 99.994
21.2 2,932.18 99.994
10,108 29,958,288 22.1 253 99.994
22.2 247
10,394 33,779,743 23.1 >500 99.994
1,842 5,479,907
3,529
5,008 24.1 >500 99.994
24.2 >500 99.994
5,875 18,458,573 24.3 >500 3,502.83 99.994




of PML patients and kidney transplant patients with stable graft function or histologically 
the reference genotype strain is shown.
1 PML 1.1 5,051
1.2 5,191
1.3 5,243
2 PML 2 5,111
3 PML 3 5,134
4 KTx 4 5,121
5 KTx 5 5,121
KTx 5,121
7 KTx 7 5,121
8 KTx 8 5,121
9 KTx 9 5,121
10 KTx 10 5,122 4 
11 KTx 11 5,122 4 
12 KTx 12.1 5,122 
12.2 5,109
13 KTx 13 5,121
14 KTx 14 5,107
15 KTx 15 5,121
KTx 5,121
5,122
17 KTx 17 5,121
18 KTx 18.1 5,122 
18.2 5,121
19 KTx 19 5,121
20b KTx 20 5,122
21 KTx 21.1 5,121
21.2 5,121
22 KTx 22.1 5,121
22.2 5,121
23 KTx 23 5,121
24 JCPVAN 24.1-24.4 5,122 4
Abbreviations: PML, progressive multifocal leukoencephalopathy; KTx, kidney transplantation; JCPVAN, 
JC polyomavirus-associated nephropathy; bp, base pair.
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 Characteristics of the short-read sequence data from twenty-four 
III 1 Plasma 174,074 149,901
2 Plasma 170,929 150,401 88.0
3 Plasma 143,719 87.8










12 Urine 129,518 72.1
Plasma 147,503 85,959 58.3
13 Urine 197,551 134,458
Plasma 179,504 102,914 57.3
14 Urine 209,807 128,873
Plasma 137,845






18 Urine 203,181 147,722 72.7
Plasma 201,098 142,933 71.1
19 Urine 171,575 118,488
Plasma 197,232
20 Urine 289,372 217,378 75.1
Plasma 322,959 231,178
21 Urine 293,225 233,812 79.7
Plasma 352,815 74.4
22 Urine 294,844 237,925 80.7
Plasma 73.0
23 Urine 308,733 251,022 81.3
Plasma 322,959 231,178
24 Urine 288,023 230,811 80.1
Plasma 281,712 217,932 77.4
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